To validate our findings that a type I/II IFN response is, in part, a driver of the anti-tumor immune response following LNP-CTNNB1 treatment (Fig. 4f, g), we treated β-M mice with IFNγ 3× weekly for 5 weeks, which led to a significant decrease in tumor burden (Fig. 4h–j) accompanied by increases in S100A8/9-positive cells, a marker for M1-like macrophages, when compared to vehicle control group (Fig. 4k). This evidence concerns the gene CTNNB1 and neoplasm.